Promising advancements in mAb114, also known as ansuvimab or Ebanga, are bringing renewed hope to Ebola patients amid the ongoing Bundibugyo strain outbreak affecting the Democratic Republic of Congo and Uganda. This single monoclonal antibody therapy, which has already demonstrated impressive results in previous outbreaks, is now at the center of expanded clinical trials and emergency response efforts as health authorities work to contain the current Public Health Emergency of International Concern.
Originally developed from the blood of an Ebola survivor by researchers at the National Institutes of Health and partners, mAb114 works by targeting the Ebola virus glycoprotein. It prevents the virus from entering human cells, effectively neutralizing it. In the landmark PALM clinical trial conducted during the 2018-2020 DRC outbreak, mAb114 significantly reduced mortality compared to earlier treatments like ZMapp. Patients receiving the antibody achieved survival rates around 66-70%, a major improvement over historical fatality rates that often exceeded 50-70% without effective intervention.
The treatment’s single-dose intravenous administration makes it particularly practical in challenging outbreak settings where multiple infusions can be logistically difficult. Administered over approximately one hour, mAb114 offers a simpler protocol that supports faster deployment in field hospitals and treatment centers. Its established safety profile, including use in adults, children, and even neonates born to infected mothers, adds to its appeal for broad application.
New Momentum in 2026 Trials
With the current cross-border Ebola situation escalating, researchers and organizations including the WHO, Africa CDC, and pharmaceutical partners are accelerating access to and further evaluation of mAb114. New trial phases are focusing on the Bundibugyo variant, optimal dosing strategies in combination with supportive care, and real-world effectiveness in diverse patient populations. Early data from ongoing compassionate use and expanded access programs suggest the antibody continues to deliver strong outcomes when given early in the course of infection.
Experts highlight mAb114’s advantages in resource-limited environments. Unlike some complex cocktails, this single antibody is relatively straightforward to store and administer, which is critical in remote areas with limited cold-chain infrastructure. Production scaling efforts by partners like Ridgeback Biotherapeutics and manufacturing collaborators aim to ensure sufficient supplies reach affected regions quickly.
Combination Approaches and Future Outlook
While mAb114 performs well as a standalone therapy, researchers are also exploring its potential in combination with other antivirals or antibodies like REGN-EB3 (Inmazeb) to further boost survival rates, especially in patients with high viral loads or advanced disease. Recent nonhuman primate studies and modeling analyses continue to support the value of these immune-based treatments, though experts emphasize that best supportive care — including fluid management, symptom relief, and infection control — remains foundational.
The progress with mAb114 represents a broader shift in Ebola management from purely supportive care to targeted, effective therapeutics. Health officials stress that rapid diagnosis, contact tracing, and community engagement, paired with these medical tools, offer the best path to controlling outbreaks.
As trials advance and data accumulates, mAb114 stands as a beacon of scientific progress against one of humanity’s most feared viruses. Its success could not only save lives in the current emergency but also strengthen preparedness for future Ebola threats. Continued investment in monoclonal antibody research and local manufacturing capacity in Africa will be key to ensuring these life-saving treatments reach those who need them most.
For patients, families, and frontline healthcare workers battling the latest outbreak, these developments provide tangible reasons for optimism in what has historically been a devastating disease.
